4Q Revenues: $6.0 billion (-2%)
4Q Earnings: $858.2 million (-27%)
FY Revenues: $24 billion (+5%)
FY Earnings: $4.3 billion (-14%)
Comments: U.S. revenue was down 4% to $3.3 billion due to the loss of patent exclusivity for Zyprexa and Gemzar. Revenue outside the U.S. remained flat at $2.8 billion due to increased volume and the positive impact of foreign exchange rates, offset by lower prices. For the year revenue in the U.S. was $13.0 billion (+1%). Revenue outside the U.S. increased 11% to $11.3 billion due to increased demand and the positive impact of foreign exchange rates, partially offset by lower prices. Zyprexa sales were $749.6 million in the quarter, down 44%, and $4.6 billion for the year (-8%). Cymbalta sales were $1.2 billion in the quarter (+20%), and $4.2 billion for the year (+20%). Alimta sales were $638.1 million in the quarter (+12%), and $2.5 billion for the year (+11%). Humalog sales increased 21% in the quarter to $662.0 million, and 15% for the year to $2.4 billion. Cialis sales in the quarter were up 6% to $494.2 million and up 10% for the year to $1.9 billion. Gemzar sales were $92.6 million, down 62% in the quarter, and $452.1 million for the year, down 61%.